665
Participants
Start Date
October 9, 2018
Primary Completion Date
October 16, 2019
Study Completion Date
October 16, 2019
High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated)
Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated)
Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)
Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated)
Pharmaceutical form: Solution for injection Route of administration: IM
FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)
Pharmaceutical form: Solution for injection Route of administration: IM
Investigational Site Number 8400002, Atlanta
Investigational Site Number 8400001, Miami
Investigational Site Number 8400013, El Dorado
Investigational Site Number 8400015, Newton
Investigational Site Number 8400009, Wichita
Investigational Site Number 8400007, Metairie
Investigational Site Number 8400003, Salt Lake City
Investigational Site Number 8400012, Salt Lake City
Investigational Site Number 8400005, Salt Lake City
Investigational Site Number 8400010, Las Vegas
Investigational Site Number 8400004, San Diego
Investigational Site Number 8400011, Warwick
Investigational Site Number 8400014, West Jordan
Investigational Site Number 1241003, Montreal
Investigational Site Number 1241002, Pierrefonds
Investigational Site Number 1241001, Québec
Sanofi Pasteur, a Sanofi Company
INDUSTRY